samedan logo

 
 
spacer
home > ebr > summer 2004 > apoptosis and chemotherapy: helping cancer cells to die
PUBLICATIONS
European Biopharmaceutical Review

Apoptosis and Chemotherapy: Helping Cancer Cells to Die

For an organism to develop multicellular tissues and organs, and to maintain cellular homeostasis during adulthood, the formation of new cells needs to be co-ordinated with the elimination of redundant and damaged cells. Apoptosis is the morphological manifestation of programmed cell death; the predominant mechanism that opposes and compliments cell proliferation. An imbalance between cell birth and death has pathological consequences: many chronic and acute degenerative disorders, as well as immunodeficiency diseases and infertility, are characterised by abnormally high rates of cell death in certain tissues. Conversely, suppression or retardation of apoptosis are distinguishing features in autoimmunity and cancer. Here I shall confine my discussion to the impact our current understanding of apoptotic signalling, as well as the mechanics of apoptosis, have on oncology drug discovery and development. Selective activation of programmed cell death in cancer cells is particularly desirable because apoptosis, as opposed to necrosis and other catastrophic cell injuries, leads to complete destruction and eradication of the aberrant cells without inflammatory and immunological side-effects.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Peter M Fischer, Head of Discovery Research at Cyclacel Limited

Peter M Fischer received his PhD from Deakin University, Australia. He has worked in academia, as well as the biotechnology and pharmaceutical industries on peptidomimetic and traditional medicinal chemistry projects related to drug discovery. For the last six years, he has been with the cancer research company Cyclacel, Scotland, for whom he established structure-based design and medicinal chemistry capabilities. He is currently Head of Discovery Research and focuses on cell cycle-related drug discovery targets, including CDKs and other protein kinases.

spacer
Peter M Fischer
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Registration Opens for Inaugural HPAPI USA Conference in October

The HPAPI global market is growing at an ever-increasing rate of CAGR at 8.6% that is projected to reach USD $31.56 Billion by 2025, with a significant segment market of HPAPI being oncology ADC which is at a CARG of a staggering 20%. The continual elevation of HPAPI potencies along with toxicity will further drive the needs for more cutting-edge containment solutions and best practices guidelines to ensure workers safety.
More info >>

White Papers

How To Increase Efficiency, Customer Satisfaction and Reduce Cost

AC Labels

A customer of Riverside Medical had required a complex four-part 'piggy back' label. The labels needed to be specially constructed to facilitate removal in parts at various stages of its use for quality control traceability. This label needed to carry variable data elements of LOT numbers, batch numbers and product descriptions, and also a secondary gamma indicator label placed on each of its 4 sections to prove its sterility following sterilisation.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement